Reminders Please rename yourself with your name and practice - PowerPoint PPT Presentation

Reminders • Please rename yourself with your name and practice location in the “Manage Participants” box. • Please enter your name and practice location into the “Chat” to record your attendance. • Use the “Chat” feature to ask questions and receive survey links. • Please remember to “Mute” your microphone unless speaking. • Call our Tech Team at 440-796-2221 if you have audio or visual problems. • If you can’t connect to audio via computer, or you lose computer audio at anytime, you can call in to the clinic at: 646-876-9923; meeting ID: 850 112 117. 1

Structure of ECHO Clinics Duration Item 5 minutes Introductions, roll call, announcements 25 minutes Didactic presentation, followed by Q&A 25 minutes Case Study presentation and discussion 5 minutes Wrap-up/Post-Clinic Survey completion 2

Cardi-OH ECHO Reducing the Burden of Hypertension Thursday, February 27, 2020 3

Disclosure Statements The following planners, speakers, moderators, and/or panelists of the CME activity have financial relationships with commercial interests to disclose: • Adam T. Perzynski, PhD reports being co-founder of Global Health Metrics LLC, a Cleveland-based software company and royalty agreements for forthcoming books with Springer publishing and Taylor Francis publishing. • Brian Bachelder, MD received funds for his role as Physician Advisor at VaxCare. • SiranM. Koroukian, PhD received grant funds for her role as a subcontractor on a study funded by Celgene. • Christopher A. Taylor, PhD, RDN, LD, FAND reports grant funding and travel support for his role as a consultant, researcher, and presenter for Abbott Nutrition, and is also a member of the Scientific Advisory Council of Viocare, Inc. • Jackson T. Wright, Jr., MD, PhD reports research support from the NIH and Ohio Department of Medicaid and consulting with NIH, AHA, and ACC. • These financial relationships are outside the presented work. All other planners, speakers, moderators, and/or panelists of the CME activity have no financial relationships with commercial interests to disclose. 4

Special Populations: African Americans Jackson T. Wright, Jr., MD, PhD, FACP, FAHA Emeritus Professor of Medicine Director, Clinical Hypertension Program Division of Nephrology and Hypertension University Hospitals Cleveland Medical Center Case Western Reserve University 5

Objectives • Briefly describe the epidemiology and impact of hypertension among African Americans. • List and describe a minimum of two guideline-based recommendations tailored for the treatment of hypertension among African Americans. • Describe a culturally sensitive approach to recommending lifestyle and medication treatment for individual adult African American patients. 6

Prevalence of Hypertension Based on 2 SBP/ DBP Thresholds*† SBP/DBP ≥130/80 mm Hg or Self - SBP/DBP ≥140/90 mm Hg or Self -Reported Reported Antihypertensive Antihypertensive Medication‡ Medication† Overall, crude 46% 32% Men Women Men Women (n=4717) (n=4906) (n=4717) (n=4906) Overall, age-sex adjusted 48% 43% 31% 32% Age group, y 20–44 30% 19% 11% 10% 45–54 50% 44% 33% 27% 55–64 70% 63% 53% 52% 65–74 77% 75% 64% 63% 75+ 79% 85% 71% 78% Race-ethnicity § Non-Hispanic White 47% 41% 31% 30% Non-Hispanic Black 59% 56% 42% 46% Non-Hispanic Asian 45% 36% 29% 27% Hispanic 44% 42% 27% 32% The prevalence estimates have been rounded to the nearest full percentage. *130/80 and 140/90 mm Hg in 9623 participants (≥20 years of age) in NHANES 2011 –2014. †BP cutpoints for definition of hypertension in the present guideline. ‡BP cutpoints for definition of hypertension in JNC 7. § Adjusted to the 2010 age-sex distribution of the U.S. adult population. 7 BP indicates blood pressure; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic blood pressure .

Morbidity and Mortality in AA Hypertensive Patients • Hypertension occurs at younger age and more resistant to treatment • Mortality in African American males—30% hypertension- related, females—20% • Nonfatal strokes—1.3 x greater than whites • Fatal strokes—1.8 x greater than whites • Heart disease deaths—1.5 x greater than whites • End-stage renal disease—4.2 x greater than whites (HTN- related—20 x greater) • Numbers have changed little over past decade 8

Social Determinants of Health • Socioeconomic status • Social challenges associated with Race, ethnicity • Social support • Culture and language • Access to care • Residential environment • Above mediated via psychological, behavioral,and biologic mechanisms AHA Scientific Statement; Havranek EP, et al. Circ 2015;132:873-98 . 9

10

Hypertension Change Package Algorithm 11

Kaiser Improvement 12

BP Control VAMCs 2000-2010 13

14 Egan BR, et al. HTN 2018; 72:1320-1327

Selected blood pressure (BP) medications filled in adults on Medicaid with uncontrolled BP Calendar years 2017-2018 (N=1549) 40% 36.41% 35% 30.86% 30.15% 30% 23.95% 25% 20% 15% 9.49% 8.39% 10% 5.75% 5% 2.07% 0% 15 Ohio Department of Medicaid’s (ODM’s) Chronic Conditions Quality Collaborative Ohio MEDTAPP funded ODM Hypertension Quality Improvement Project, 2019. https://grc.osu.edu/Projects/MEDTAPP/HypertensionQIP

Hypertension Drug Treatment Algorithm In addition to lifestyle change: Start a thiazide diuretic (chlorthalidone 25 mg ½ tab once daily. [Need pill cutter]) OR Amlodipine 5 mg once daily. BLOOD PRESSURE AT GOAL? Yes No Add an ACEI/ARB (e.g. lisinopril 10-40 mg once daily or losartan 50-100 mg once daily. Can be added at Step 1 if CKD present (esp with proteinuria) or BP> 20 mmHg above goal. Yes No If on chlorthalidone, increase to 25 mg once daily If on amlodipine, increase to 10 mg/day. Yes Add chlorthalidone to 12.5-25 Add amlodipine 5-10 mg once daily). mg/day mg once daily). Yes No Add spironolactone 25-50 mg once daily if K< 4.5 Yes No Add a beta blocker if HR > 70 (e.g. metoprolol ER 50 -200 mg daily) or guanfacine 1-3 mg daily (not clonidine) Yes No 16 Continue current therapy Consider non-adherence issues, secondary causes of HTN, additional agents like hydralazine or minoxidil, or referral to a HTN specialist.

Systolic BP During Follow-up Non-Hispanic Non-Hispanic Hispanics Whites Blacks 143 143 143 Systolic Blood Pressure (mmHg) Systolic Blood Pressure (mmHg) Systolic Blood Pressure (mmHg) 139 139 139 135 135 135 131 131 131 127 127 127 123 123 123 119 119 119 115 115 115 0 6 12 18 24 30 36 0 6 12 18 24 30 36 0 6 12 18 24 30 36 Follow-up Month Follow-up Month Follow-up Month Mean Number of Meds Mean Number of Meds Mean Number of Meds Standard: 2.0 2.0 2.0 2.0 2.0 2.0 2.0 Standard: 1.8 1.7 1.7 1.7 1.7 1.7 1.7 Standard: 1.7 1.8 1.8 1.7 1.8 1.8 1.7 Intensive: 2.0 2.9 3.0 3.0 3.1 3.1 3.1 Intensive: 1.8 2.7 2.7 2.8 2.8 2.7 2.7 Intensive: 1.8 2.6 2.7 2.7 2.7 2.7 2.7 Average post-baseline follow-up SBP mean ± SE for standard (vs intensive) group: NHW=134.7 ± 0.1 (vs 119.9 ± 0.4 ) mmHg; NHB = 135.5 ± 0.2 (vs of 121.8 ± 0.2) mmHg; Hispanic= 134.8 ± 0.3 (vs 122.6 ± 0.2) mmHg. 17 Still CH et al. Am J Hypertens 2017, https://doi.org/10.1093/ajh/hpx138

Primary Outcome in the Pre-specified Subgroups *Treatment by subgroup interaction Wright JT Jr et al. NEJM 2015; 373: 2103-2116 18

Diuretic Duration of Action and Pharmacokinetics BP↓/mg Drug Vol of Oral Bioavail Onset of Peak Half-life Duration Distribution Effect Effect (chronic (chronic dosing) dosing) HCTZ 3-4 L/kg ref ~70% 2 hr 4-6 hr 16-24 hr 40% protein bound Chlorthalidone 3-13/kg 2 ~65% 2-3 hr 2-6 hr 48-72 hr 75% protein bound (98% RBC distribution) Indapamide 20 ~93% 1-2 hr < 2 hr ~36 hr Note: Compared to HCTZ, chlorthalidone ~ twice as potent in BP lowering, more gradual onset of diuretic action, longer duration of action of BP lowering, and has larger evidence base documenting CVD reduction Carter BL, Ernst ME, Cohen JD. Hypertension 2004;43:4-9. 19 Abernathy DR, Cardiol 1992; 80:31-36

Calcium Channel Blocker Half-Life Sica DA. J Clin Hypertens 2005; 7(4) Supp 1: 21-26 20

Blood Pressure During Follow-up Low Usual Ramipril Amlodipine Metoprolol MAP MAP Goal Goal SBP 134 131 134 128* 141 (mm Hg) DBP 81 81 81 78* 85 (mm Hg) MAP 99 98 99 94* 104 (mm Hg) *Significantly different between two blood pressure goals p<0.01 Wright et al. JAMA 2002; 288:2421 21

Strategies to Improve Hypertension Treatment and Control Recommendation for Structured, Team-Based Care Interventions for Hypertension Control COR LOE Recommendation A team-based care approach is I A recommended for adults with hypertension. 22